Low circulating levels of neuregulin 4 as a potential biomarker associated with the severity and prognosis of obesity-related metabolic diseases: a systematic review
Adipocyte · 31.12.2024 · 13 (1)
DOI: 10.1080/21623945.2024.2390833 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Adipocyte, online erschienen am 20.08.2024. Verfasst von Khanyisani Ziqubu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, North-West University, Mmabatho, South Africa. Hauptthemen laut MEDLINE: Neuregulins, Biomarkers, Obesity. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation, South African Medical Research Council, Northwest University.
Abstract (Originalsprache)
BACKGROUND: Neuregulin 4 (Nrg4) is a brown adipose tissue-derived adipokine that greatly affects systemic metabolism and improves metabolic derangements. Although abnormal circulating levels of Nrg4 are common in obesity, it remains elusive whether low or elevated levels of this batokine are associated with the onset of metabolic diseases. AIM: To assess Nrg4 levels and its role as a feasible biomarker to predict the severity of obesity, gestational diabetes mellitus (GDM), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and cardiovascular diseases (CVD). METHODS: A search for relevant studies was performed systematically using prominent search engines, including PubMed, Google Scholar, and Embase, by following PRISMA guidelines. RESULTS: Ample clinical evidence reported low serum/plasma levels of Nrg4 in obesity and these were inversely proportional to the indices of metabolic syndrome, including body mass index, waist circumference, triglycerides, fasting plasma glucose, and homoeostatic model assessment for insulin resistance as well as high-sensitivity C-reactive protein. Low circulating Nrg4 levels may aid in the prediction of morbid obesity, and subsequent GDM, T2DM, NAFLD, and CVD. CONCLUSION: Current clinical evidence emphasizes that the circulating levels of Nrg4 are decreased in morbid obesity, and it also highlights that Nrg4 May serve as a potential prognostic biomarker for obesity-related metabolic diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, North-West University, Mmabatho, South Africa.
- Cochrane South Africa, South African Medical Research Council, Tygerberg, South Africa.
- Department of Biochemistry and Microbiology, University of Zululand, KwaDlangezwa, South Africa.
- School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.
ORCID-Profile: Khanyisani Ziqubu
Förderung
- National Research Foundation
- South African Medical Research Council
- Northwest University
Zitieren
APA
Ziqubu, K., Dludla, P. V., Mthembu, S. X. H., Nkambule, B., & Mazibuko-Mbeje, S. E. (2024). Low circulating levels of neuregulin 4 as a potential biomarker associated with the severity and prognosis of obesity-related metabolic diseases: a systematic review. Adipocyte, 13(1). https://doi.org/10.1080/21623945.2024.2390833
Vancouver
Ziqubu K, Dludla PV, Mthembu SXH, Nkambule B, Mazibuko-Mbeje SE. Low circulating levels of neuregulin 4 as a potential biomarker associated with the severity and prognosis of obesity-related metabolic diseases: a systematic review. Adipocyte. 2024;13(1). doi:10.1080/21623945.2024.2390833
BibTeX
@article{Ziqubu2024,
author = {Ziqubu, Khanyisani and Dludla, Phiwayinkosi V and Mthembu, Sinenhlanhla X H and Nkambule, Bongani and Mazibuko-Mbeje, Sithandiwe E},
title = {Low circulating levels of neuregulin 4 as a potential biomarker associated with the severity and prognosis of obesity-related metabolic diseases: a systematic review},
journal = {Adipocyte},
year = {2024},
volume = {13},
number = {1},
doi = {10.1080/21623945.2024.2390833}
}
EUVIMED